The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
We sought to determine whether the use of sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled a new‐user, active comparator cohort of SGLT‐2 inhibitor and dipeptidyl peptidase‐4 (DPP‐4) inhibitor users using the United Kingdom Clinical Practice Research Datalink. We fit Cox proportional hazards...
Aims
The objective of this study was to determine whether the use of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with an increased risk of melanoma and nonmelanoma skin cancer, separately, compared with the use of sulfonylureas among patients with type 2 diabetes.
Methods
Using the United Kingdom Clinical Practice Research Datalink (2007–2019), we assembled two new‐user...